Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Shares Outstanding (Weighted Average) (2016 - 2025)

CorMedix's Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $67.9 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Weighted Average) rose 18.01% year-over-year to $67.9 million; the TTM value through Jun 2025 reached $67.9 million, up 18.01%, while the annual FY2024 figure was $58.9 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q2 2025 was $67.9 million at CorMedix, up from $65.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $67.9 million in Q2 2025 and bottomed at $36.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $44.1 million (2023), against an average of $47.8 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 45.67% in 2021 before it grew 4.41% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $37.7 million in 2021, then grew by 6.92% to $40.3 million in 2022, then rose by 20.96% to $48.7 million in 2023, then increased by 20.85% to $58.9 million in 2024, then increased by 15.38% to $67.9 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Shares Outstanding (Weighted Average) are $67.9 million (Q2 2025), $65.2 million (Q1 2025), and $58.9 million (Q4 2024).